BioWorld always honors news embargoes. An early heads up gives us extra time to prepare and conduct research. We promise to keep your news confidential until the stated embargo lifts. BioWorld is the ...
On the tail of rumors that Merck & Co. Inc. and others holding stakes in Personalis Inc. might take over the firm, Chicago-based Tempus AI Inc. ended speculation by disclosing its plan to buy the ...
Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In preclinical models of HER2 and EGFR co ...
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head ...
Newronika SpA received CE mark certification for its latest adaptive deep brain stimulation (aDBS) system, which includes the ...
The synergy – or lack of it – between knockdown drugs and stabilizers in treating transthyretin (TTR)-mediated amyloid ...
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical ...
Biopharma deal value through the first half (H1) of 2026 reached $170.11 billion, surpassing every prior year in BioWorld’s ...
GSK plc is halting work with camlipixant, a P2X3 receptor antagonist, in adults with refractory chronic cough (RCC) after reporting mixed results from the Calm-1 and Calm-2 phase III trials. The first ...
Insmed Inc. has delivered further evidence of the advantages of its once-daily pulmonary arterial hypertension (PAH) drug ...
Mirador Therapeutics Inc. has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a long-acting anti-C5a antibody with potential to treat ANCA-associated ...
Indole-based compounds have been explored as antimalarial agents because they can disrupt the Plasmodium cell cycle. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results